Primary liver cancer and metastatic liver cancer are common malignant tumors in clinical practice, and their treatment is mainly surgical resection. However, most patients with liver cancer have lost the opportunity of surgery due to poor general condition and late stage of disease when they are found. Interventional therapy includes ultrasound-guided interventional therapy or X-ray (CT) guided interventional therapy. Next, we will talk about the hepatic artery embolization chemotherapy (TACE) in interventional treatment. It is a minimally invasive tumor treatment method developed in the 1980s, which is so effective in liver cancer that it is even recommended as the preferred option among non-surgical treatments. For patients with liver cancer, especially in advanced stages, hepatic artery chemoembolization is a very effective palliative treatment that can shrink the tumor and give some patients a chance for surgical treatment. It can also prolong survival for patients with intermediate to advanced stages, while greatly improving quality of life. The liver has dual blood supply from hepatic artery and portal vein, and hepatic artery is the main blood supply route for hepatocellular carcinoma. On the one hand, through direct chemotherapy, the first drug can pass through the tumor, which results in higher local drug concentration and stronger effect on killing tumor cells; on the other hand, the hepatic artery is embolized, which leads to ischemia and necrosis of tumor tissues. Therefore, hepatic artery chemoembolization is a very effective method to control tumor and reduce tumor size. The specific method is to insert the catheter through the femoral artery directly to the hepatic artery or its branches under the guidance of X ray, and the microcatheter is super-selected to the tumor blood supply artery, and the imaging will show the tumor staining. blocked. Sometimes, chemical anticancer drugs such as adriamycin, mitomycin, cis-chloramphenicol, etc. are mixed with embolic agent, and then this suspension is injected into the hepatic artery. The embolic agent in the suspension can stay in the liver tissue for a long time, and the chemotherapeutic drugs in it are also released slowly in the cancer tissue, so that it can play a long time anticancer effect, and the toxic reaction of chemotherapeutic drugs to the normal tissues of the whole body can be significantly reduced. Hepatic artery embolization chemotherapy is currently the preferred method of non-surgical treatment due to its good efficacy and low adverse effects, but it also has certain limits of application. For patients with hepatocellular carcinoma whose tumor volume exceeds 2/3 of the liver volume, portal vein thrombosis, severe portal hypertension and patients with severe cardiac, hepatic and renal insufficiency or coagulation dysfunction and low white blood cells, hepatic artery embolization chemotherapy is not suitable. Commonly used drugs for hepatic artery embolization chemotherapy include epi-amycin, mitomycin, platinum, etc. The chemotherapy regimens applied in TACE treatment of hepatocellular carcinoma vary widely throughout the world. In China, high-dose combination chemotherapy is often reported, but in Europe and the United States, single-agent chemotherapy is usually used, and in Japan, low-dose chemotherapy is usually used; some scholars even believe that embolization plays a major role in TACE, and chemotherapy drugs play little role. In our center, embolization and chemotherapy are usually used in combination. Hepatic artery embolization chemotherapy can also be combined with radiofrequency ablation (RFA), argon helium knife freezing, and anhydrous ethanol ablation (PEI) to further improve the treatment effect. As a tumor with high malignancy, recurrence rate and mortality, the treatment of hepatocellular carcinoma also requires the combination of multiple therapeutic tools.